-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ori-CAR-002 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ori-CAR-002 in Refractory Multiple Myeloma Drug Details:Gene therapy is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ori-CAR-002 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ori-CAR-002 in Relapsed Multiple Myeloma Drug Details:Gene therapy is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iadademstat in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Iadademstat in Refractory Acute Myeloid Leukemia Drug Details:Iadademstat (ORY-1001) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iadademstat in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Iadademstat in Relapsed Acute Myeloid Leukemia Drug Details:Iadademstat (ORY-1001) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iadademstat in Neuroendocrine Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Iadademstat in Neuroendocrine CarcinomaDrug Details:Iadademstat (ORY-1001) is under development for the treatment of small cell lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vafidemstat in Borderline Personality Disorder (BPD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vafidemstat in Borderline Personality Disorder (BPD) Drug Details: Vafidemstat (ORY-2001) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vafidemstat in Attention Deficit Hyperactivity Disorder (ADHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vafidemstat in Attention Deficit Hyperactivity Disorder (ADHD) Drug Details: Vafidemstat (ORY-2001) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Immunoart in Graft Versus Host Disease (GVHD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Immunoart in Graft Versus Host Disease (GVHD) Drug Details: ImmunoArt is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – S-055746 in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. S-055746 in Mantle Cell Lymphoma Drug Details: S-055746 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IBI-110 in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IBI-110 in Hepatocellular Carcinoma Drug Details: IBI-110 is under development for the treatment of refractory...
-
Sector Analysis
![]()
Business of the Ligue 1 2023-24 – Property Profile, Sponsorship and Media Landscape
Business of Ligue 1 Report Overview The Ligue 1 is estimated to generate an estimated annual sponsorship revenue of $45.45 million in the 2023-24 season. Ligue 1 is the top professional soccer league in France, considered to be one of the best leagues in the world. It is grouped with the top leagues in England, Germany, Italy, and Spain, to be known as the ‘big five’. The reputation of these leagues is based on a long-standing history of attracting the...
-
Product Insights
![]()
Ori Gamma Lux 1 – Calamocha Meat Processing Plant – Aragon
Equip yourself with the essential tools needed to make informed and profitable decisions with our Ori Gamma Lux 1 - Calamocha Meat Processing Plant - Aragon report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
![]()
Ori Gamma Lux 1 – 50 Bothwell Street Office Redevelopment – Glasgow City
Equip yourself with the essential tools needed to make informed and profitable decisions with our Ori Gamma Lux 1 - 50 Bothwell Street Office Redevelopment - Glasgow City report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Company Insights
![]()
Vmware – Digital Transformation Strategies
VMware is strengthening its focus on the use of key disruptive technologies to enhance its business operations and service offerings. To do so, it is tapping into key disruptive technologies including AI, big data, cybersecurity, and blockchain, among others. The annual ICT spending of VMware is estimated at $804.0 million for 2022. A major share of this spending is earmarked for acquiring software, ICT services and hardware from vendors. VMware, (VMware) offers multi-cloud services for different apps and virtualization technologies....
-
Company Profile
![]()
The Hour Glass Ltd – Company Profile
The Hour Glass Ltd (Hour Glass) is a retailer of watches, jewelry, and other luxury products. It offers various watches under Jaquet Droz, Kari Voutilainen, Junghans, MB&F, Rolex, Omega, Rado, NOMOS Glashutte, Piaget, Oris, Tissot, TAG Heuer, Zenith, Rado, Grand Seiko, Hublot and Panerai brand names. The company sells its products through retail stores and online platforms. Its network of standalone brand and multi-brand boutiques are strategically located in the key luxury retail corridors across Asia-Pacific region. Hour Glass has...
Add to Basket -
Product Insights
![]()
Net Present Value Model: Iadademstat
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Iadademstat Drug Details Iadademstat (ORY-1001) is...
-
Product Insights
![]()
Net Present Value Model: Vafidemstat
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Vafidemstat Drug Details Vafidemstat (ORY-2001) is...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – vafidemstat
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry vafidemstat Drug Details Vafidemstat (ORY-2001) is under development for the treatment of Phelan-McDermid Syndrome,...
-
Product Insights
![]()
Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Alzheimer is a progressive neurologic disorder beginning with mild memory loss. It could possibly lead to a loss of the ability to carry on a conversation and respond to the environment. The Alzheimer pipeline market research report provides comprehensive information about the Alzheimer pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Company Insights
![]()
Inter IKEA Holding B.V – Digital Transformation Strategies
Inter IKEA Holding B.V. (IKEA Group) has been focusing on using big data, 3D modeling, mobile, and the Internet of Things (IoT) to digitally transform its operations. The annual ICT spending of IKEA Group was estimated at $674.4 million for 2022. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. IKEA Group manufactures, distributes, and retails furniture and home decor products. The company’s product portfolio includes beds and mattresses, decoration materials, flooring,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.